A medicament set adapted to regulate multiple receptors simultaneously in patients experiencing diabetic peripheral neuropathy pain, the medicament set comprising: at least three distinct and separate medicaments for treating diabetic peripheral neuropathy pain, the at least three medicaments being a first medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising polylactic glycolic acid (PLGA) micro-particles being loaded with a sodium channel blocker and local anesthetic drug, a second medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with a sodium channel blocker and anti-convulsant drug, and a third medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with an anti-inflammatory drug.

Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed. ##STR00001##

Metastatic triple negative breast cancer (TNBC) still carries a dismal prognosis with the current treatment paradigms. The effectiveness of drug treatment for many solid tumors such as TNBC is limited by tumor heterogeneity, lack of tumor specificity, off-target toxicities, and transient therapeutic action(s). Strategies that provide tumor-specific, sustained concentrations of drugs to the tumors and tumor receptor-specific binding, while reducing off-target effects are needed to ensure sufficient tumor cell uptake within the primary and metastatic tumor microenvironment. The decreased non-specific adhesivity, receptor-targeted nanoparticle formulations (“DART” nanoparticles) of the invention were assessed for clinical potential in directing biological agents to the cell surface receptor Fn14, which is expressed in many solid cancer types, including TNBC primary tumors and metastatic lesions. They are contemplated for use against solid tumors, particularly brain tumors such as glioblastoma and breast cancer, including metastatic breast cancer.

Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises

##STR00001##

wherein R′ is —H or —CH.sub.3, wherein R is —NR.sup.1R.sup.2, wherein R.sup.1 and R.sup.2 are alkyl groups, wherein R.sup.1 and R.sup.2 are the same or different, wherein R.sup.1 and R.sup.2 together have from 5 to 16 carbons, wherein R.sup.1 and R.sup.2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.

A pharmaceutical composition comprises a metal nanoparticle having an average diameter of about 0.5 nm to about 5 nm. The composition may be used to treat cancer or an anosmia-related disease.

The present disclosure provides peptides that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, particularly nanoparticle compositions, comprising the same and to methods of using the peptides to treat atherosclerosis, thrombosis, stroke, heart attack, inflammation, acute respiratory distress syndrome (ARDS), autoimmune diseases, AV Fistula for hemodialysis or organ transplantation.

The invention relates to a pharmaceutical composition of the cores of microgranules containing pancreatin, cetyl alcohol, poloxamer 407 in predetermined quantities, the production method, as well as the production of the water-based enteric-coated microgranules. Furthermore, the resulting oral dosage form does not contain residual acetone. The technical result is in achieving higher stability of the cores and the enteric-coated microgranules, respectively, while maintaining the good solubility of the enteric-coated microgranules, which allows the application of the claimed pancreatin microgranules for the preparation of safe and non-toxic drugs for the treatment of digestive disorders.

Provided is a microsphere comprising a bead coated with a first calcium-containing mineral. Also provided is a method of producing a microsphere. Additionally, a method of administering a compound to a vertebrate is provided.

The invention is directed to a biodegradable, phase separated, thermoplastic multi-block copolymer, to a process for preparing a biodegradable, phase separated, thermoplastic multi-block copolymer, to the use of a biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymer, and to a composition for the delivery of at least one biologically active compound to a host.

The biodegradable, phase separated, thermoplastic multi-block copolymer of the invention comprises at least one amorphous hydrolysable pre-polymer (A) segment and at least one semi-crystalline hydrolysable pre-polymer (B) segment, wherein said multi-block copolymer under physiological conditions has a T.sub.g of 37° C. or less and a T.sub.m of 50-110° C.; the segments are linked by a multifunctional chain extender; the segments are randomly distributed over the polymer chain; and the pre-polymer (B) segment comprises a X-Y-X tri-block, wherein Y is a polymerisation initiator, and X is a poly(p-dioxanone) segment with a block length expressed in p-dioxanone monomer units of 7 or more.

Provided herein are poly(ether ester) multi-block copolymers (PEE-MBCP). Also provided herein are injectable delivery systems or pharmaceutical compositions, comprising a PEE-MBCP provided herein, either alone or in combination with a binding protein, such as abicipar. Also provided herein are methods of using these injectable delivery systems or pharmaceutical compositions provided herein for the treatment of ocular disorders.